Bolt Biotherapeutics (BOLT) is scheduled to report Q1 earnings on May 11, 2026. Analysts estimate EPS of $-3.69 and quarterly revenue of $1.50M.

In the most recent quarter (Q4), Bolt Biotherapeutics reported EPS of $-3.84, beating estimates of $-5.02 by 0.24%. Revenue came in at $2.50M, exceeding the estimate of $914.35K by 1.73%.

Bolt Biotherapeutics has beaten EPS estimates in 4 consecutive quarters.

Over the last 4 quarters, Bolt Biotherapeutics has averaged an EPS surprise of 0.23% and a revenue surprise of 1.24%.